免疫治疗时代下小细胞肺癌的诊疗进展
小细胞肺癌(SCLC)占肺癌诊断病例的15%,广泛期患者此前超过15年无临床相关治疗进展,免疫检查点抑制剂(ICI)已将阿替利珠单抗或度伐利尤单抗联合铂类-依托泊苷确立为一线新标准。本综述总结ICI相关治疗进展,并讨论老年、体能状态差或脑转移患者的挑战与在研免疫策略。
要点
- 阿替利珠单抗或度伐利尤单抗联合铂类-依托泊苷为广泛期SCLC一线新标准。
- SCLC中免疫联合化疗的获益幅度较转移性非小细胞肺癌更有限。
- SCLC的免疫抑制表型可能削弱ICI疗效并解释两类肺癌的结局差异。
核心结论
- 免疫检查点抑制剂联合化疗已成为广泛期SCLC一线治疗新标准,但获益幅度较转移性非小细胞肺癌更有限。
研究设计与样本
- 本文为综述,总结SCLC免疫治疗近期进展、特殊人群挑战及在研免疫策略。
主要发现
- 广泛期SCLC在超过15年无临床相关治疗进展后,成为第二种因ICI改变治疗范式并改善总生存的胸部恶性肿瘤。
- 阿替利珠单抗或度伐利尤单抗联合铂类-依托泊苷被视为SCLC一线新标准治疗。
- SCLC的免疫抑制表型在削弱ICI疗效中起重要作用,可能解释其与NSCLC的结局差异。
临床怎么用
- 广泛期SCLC一线可考虑阿替利珠单抗或度伐利尤单抗联合铂类-依托泊苷的免疫-化疗策略。
- 对老年、体能状态差或伴脑转移的SCLC患者,需关注免疫治疗策略的当前挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Small cell lung cancer (SCLC) is an aggressive malignancy accounting for 15% of all diagnosed cases of lung cancer. After >15 years without any clinically relevant therapeutic advances, extensive-disease SCLC has become the second thoracic malignancy for which immune checkpoint inhibitors (ICIs) have shifted the treatment paradigm to improve overall survival. Today, atezolizumab or durvalumab in combination with platinum-etoposide chemotherapy is considered the new standard of care in the first-line setting in SCLC. However, the magnitude of benefit with this immune-chemotherapy strategy in SCLC is more modest than that observed in metastatic non-small-cell lung cancer patients. The immunosuppressive phenotype of SCLC plays an important role in hampering ICI efficacy and may explain the differences in outcomes between these two types of lung cancer. In this review, we provide a summary of recent therapeutic advances in SCLC in light of ICIs, as well as current challenges of this strategy in patients who are elderly, have poor performance status or brain metastases. We also address future perspectives of immunotherapeutic strategies currently in clinical development for these patients.
引用
- Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021. PMID: 33737119. doi:10.1016/j.annonc.2021.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。